Brief: Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission
02/04/2024 14:39
April 2 (Reuters) - Mira Pharmaceuticals Inc MIRA.O :
* MIRA PHARMACEUTICALS ANNOUNCES ENCOURAGING PRECLINICAL
RESULTS
ADVANCING KETAMIR-2 TOWARDS POTENTIAL YEAR-END IND SUBMISSION
* MIRA PHARMACEUTICALS INC: INITIAL TOXICOLOGY ASSESSMENTS
OF
KETAMIR-2 PROVIDE A FAVORABLE SAFETY PROFILE
* MIRA PHARMACEUTICALS INC: STUDIES INDICATE POTENTIAL FOR
KETAMIR-2 TO BE METABOLIZED EFFECTIVELY AND SAFELY
Source text for Eikon: ID:nPn8hLwqVa
Further company coverage: MIRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing